RxDoctor Payments Data

Reza Govashiri, MD

Internal Medicine · Laguna Hills, CANPI 1255346797

Payments from drug & device makers

$2,719in general payments, 2019–2025

Across 88 payments — averaging $30.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AstraZeneca$333
  • Novo Nordisk$239
  • Amgen$186
  • Edwards Lifesciences$145
  • Lilly USA, LLC$101
  • plus $657 from 15 others

What the payments were for

  • Food & beverage$2,70599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,719 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$165,227
Medicare patients
112
Services billed
1,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$67,992
OzempicSemaglutide42$40,919
EliquisApixaban29$22,686
MounjaroTirzepatide16$19,765
LinzessLinaclotide31$19,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$19,202
XareltoRivaroxaban13$16,273
Atrovent HfaIpratropium Bromide13$6,036
LumiganBimatoprost12$3,090
Atorvastatin Calcium177$2,053
Candesartan Cilexetil24$1,905
Rosuvastatin Calcium83$1,799
Levothyroxine Sodium139$1,759
SynthroidLevothyroxine Sodium24$1,527
Losartan Potassium88$1,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$239$40,91942 claims
AbbVieLinzess, Lumigan, Synthroid$47$23,95767 claims
PfizerEliquis$98$22,68629 claims
Lilly USA, LLCMounjaro$101$19,76516 claims
GSKTrelegy Ellipta$25$19,20221 claims
Johnson & JohnsonXarelto$57$16,27313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →